All In Biotech

Drug Trial Radar · NCT06333314

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression

Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 23, 2024

Primary completion

Oct 2028

Study completion Sep 2030

Sponsor

Lead sponsor
UNICANCERAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute, France; GlaxoSmithKline
First posted
Mar 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite instability (MSI) non-resectable metastatic or locally advanced non-colorectal and non-endometrial cancers compared to the standard of care chemotherapy. Adult patients (aged ≥18 years) with histologically confirmed dMMR/MSI duodenum and small bowel adenocarcinoma, gastric and oeso-gastric junction (OGJ) adenocarcinoma with combined positive score (CPS)\<5, pancreatic adenocarcinoma, ampulla of vater adenocarcinoma, adrenocortical carcinoma, carcinoma of unknown primary site, neuroendocrine carcinoma (Grade3) all primary, and soft tissue sarcoma (except Gastro-Intestinal Stromal Tumor) will be included in this study. They will be randomized and treated with either dostarlimab (experimental arm A), or chemotherapy (control arm B). Patients with documented disease progression following the first line chemotherapy (Arm B) may be eligible for crossover to be treated with dostarlimab, with the same schedule as arm A.

Conditions

  • Pancreatic Adenocarcinoma
  • Ampulla of Vater Carcinoma
  • Adrenocortical Carcinoma
  • Neuroendocrine Carcinoma
  • Soft Tissue Sarcoma
  • Small Bowel Adenocarcinoma
  • Duodenum Adenocarcinoma
  • Gastric Adenocarcinoma

Interventions

  • DostarlimabDrug

    Anti-PD-1 monoclonal antibody

  • ChemotherapyDrug

    * mFOLFOX6 or FOLFIRI or XELOX regimen * FOLFOX or XELOX or TFOX regimen * FOLFIRINOX or gemcitabine-nab-paclitaxel or gemcitabine monotherapy. * Cisplatin and gemcitabine cisplatin or CAPOX or mFOLFOX6. * Etoposide-cisplatin-doxorubicin or mitotane * Cisplatin and gemcitabine or carboplatin and paclitaxel * Etoposide-cisplatin or etoposide-carboplatin * Doxorubicin and ifosfamide or doxorubicin monotherapy or doxorubicin and trabectedin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: From randomization until disease progression or death from any cause, up to 3 years.

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Institut de Cancérologie de l'Ouest

    Angers, France · Not yet recruiting

  • Institut du Cancer Avignon-Provence

    Avignon, France · Not yet recruiting

  • CHU Jean Minjoz

    Besançon, France · Not yet recruiting

  • CHU Morvan

    Brest, France · Not yet recruiting

  • Centre François Baclesse

    Caen, France · Not yet recruiting

  • Centre Jean Perrin

    Clermont-Ferrand, France · Not yet recruiting

  • CHU - Henri Mondor

    Créteil, France · Not yet recruiting

  • Centre Georges François Leclerc

    Dijon, France · Not yet recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Hôpital la Timone

    Marseille, France · Not yet recruiting

  • Institut Paoli Calmettes

    Marseille, France · Not yet recruiting

  • Institut de Cancérologie de Lorraine

    Nancy, France · Not yet recruiting

  • Institut Mutualiste Montsouris

    Paris, France · Not yet recruiting

  • CHU de Bordeaux - Hôpital Haut -Lèvêque

    Pessac, France · Not yet recruiting

  • CHU de Poitiers

    Poitiers, France · Not yet recruiting

  • Institut Jean Godinot

    Reims, France · Not yet recruiting

  • Centre Eugène Marquis

    Rennes, France · Not yet recruiting

  • CHU de Rouen

    Rouen, France · Not yet recruiting

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain, France · Not yet recruiting

  • CHU de Toulouse Hôpital Rangueil

    Toulouse, France · Not yet recruiting

  • Gustave Roussy Grand Paris

    Villejuif, France · Not yet recruiting

  • Hôpital Saint-Antoine

    Paris, Île-de-France Region, France · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.